| Date Filed | Type | Description |
| 09/27/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
4
| Ainsworth Sean (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 10,976 shares
@ $0
Granted 9,639 options
@ $3.83, valued at
$36.9k
|
|
| 06/08/2023 |
4
| MANUSO JAMES S J (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 10,976 shares
@ $0
Granted 9,639 options
@ $3.83, valued at
$36.9k
|
|
| 06/08/2023 |
4
| Pepose Jay (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 10,976 shares
@ $0
Granted 9,639 options
@ $3.83, valued at
$36.9k
|
|
| 06/08/2023 |
4
| Benton Susan (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 10,976 shares
@ $0
Granted 9,639 options
@ $3.83, valued at
$36.9k
|
|
| 06/08/2023 |
4
| Gallagher Cam (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 10,976 shares
@ $0
Granted 9,639 options
@ $3.83, valued at
$36.9k
|
|
| 06/02/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Investor presentation, Quarterly results |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/26/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/30/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Sooch Mina reports a 5.5% stake in Ocuphire Pharma, Inc. |
| 02/14/2023 |
5
| Sooch Mina (President and CEO) has filed a Form 5 on Ocuphire Pharma, Inc. |
| 02/14/2023 |
5
| Ainsworth Sean (Director) has filed a Form 5 on Ocuphire Pharma, Inc. |
| 01/25/2023 |
8-K
| Investor presentation |
| 01/12/2023 |
4
| Sooch Mina (President and CEO) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 134,456 shares
@ $0
Granted 201,683 options to buy
@ $3.5, valued at
$705.9k
|
|
| 01/12/2023 |
4
| MANUSO JAMES S J (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 18,544 shares
@ $0 |
|
| 01/12/2023 |
4
| Pepose Jay (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 13,013 shares
@ $0
Granted 33,291 options to buy
@ $3.5, valued at
$116.5k
|
|
| 01/12/2023 |
4
| Rodgers Richard J (Director) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 20,822 shares
@ $0 |
|
| 01/12/2023 |
4
| Hoffmann Bernhard (SVP of Corp. Dev. & Ops & Sec.) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 46,608 shares
@ $0
Granted 69,912 options to buy
@ $3.5, valued at
$244.7k
|
|
| 01/12/2023 |
4
| Zaremba Rabourn Amy (SVP of Finance) has filed a Form 4 on Ocuphire Pharma, Inc.|
Txns:
| Granted 46,608 shares
@ $0
Granted 69,912 options to buy
@ $3.5, valued at
$244.7k
|
|
|